Cardiomyopathy Trial, Recruiting NCT05651919 Sponsor: Hospices Civils de Lyon Condition: Cardiomyopathy
Back to Cardiomyopathy

Cardiomyopathy Trial, Recruiting

NCT05651919
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are attending a scheduled cardiology or diabetes/hormone specialist follow-up appointment
  • You are willing to fast before having a blood sample taken
  • You are between 40 and 85 years old (inclusive)
  • You do not object to taking part in this research
  • You agree to have your biological samples stored and used for genetic analysis
  • You fit into one of four specific groups: (1) no type 2 diabetes or metabolic syndrome and no heart failure; (2) no type 2 diabetes or metabolic syndrome but diagnosed with a specific type of heart failure (HFpEF or HFmrEF); (3) diagnosed with both type 2 diabetes and metabolic syndrome but no heart failure; or (4) diagnosed with both type 2 diabetes and metabolic syndrome and also diagnosed with HFpEF or HFmrEF

Who may not be able to join:

  • You have a history of certain heart conditions (such as significant valve disease, heart damage from radiation or chemotherapy, or a protein build-up condition called amyloidosis) other than the specific types of heart failure mentioned above
  • You currently have or recently had an active infection or widespread inflammation in your body
  • You have a known history of blocked heart arteries (coronary artery disease)
  • Your blood pressure is not well controlled (above 160/100 mmHg)
  • You are pregnant or breastfeeding
  • You are currently under a court or government-ordered restriction of personal freedom
  • You are currently receiving psychiatric inpatient care
  • You are under a legal protection order such as guardianship or curatorship
  • You are already taking part in another clinical trial that has an active exclusion period
  • You have significant kidney disease where your kidneys are working at a low level (confirm with trial site)
  • Depending on which group you may qualify for, having or not having diabetes, metabolic syndrome, or a certain level of heart pumping function may affect your eligibility (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 0427856691

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
23 May 2023
Est. completion
23 May 2028

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Comparison of Initial level of Ca2+ fluxes from T2D+MS patients vs non T2D+MS patients, according to the presence or not of HFpEF or HFmrEF; Comparison of amplitude of Ca2+ fluxes from T2D+MS patients vs non T2D+MS patients, according to the presence or not of HFpEF or HFmrEF; Comparison of area under curve of Ca2+ fluxes from T2D+MS patients vs non T2D+MS patients, according to the presence or not of HFpEF or HFmrEF; Comparison of slope of the response to pharmacological stimulation of Ca2+ fluxes from T2D+MS patients vs non T2D+MS patients, according to the presence or not of HFpEF or HFmrEF...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov